

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 68154

**Title:** The effect of Shenyankangfu tablet treatment with adjuvant tacrolimus on idiopathic membranous nephropathy

**Reviewer's code:** 06129445

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Switzerland

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-07-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-07-25 23:49

**Reviewer performed review:** 2021-08-08 15:18

**Review time:** 13 Days and 15 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

The incidence of idiopathic membranous nephropathy has continued to increase in recent years, and safe and effective treatments are of significant research interest. Cyclophosphamide is commonly used in idiopathic membranous nephropathy and can achieve certain therapeutic effects, but the incidence of adverse reactions is high. Tacrolimus is a new calcineurin inhibitor that can effectively improve renal function with low dose and high safety. In this study, the authors investigated the efficacy and safety of nephritis rehabilitation tablets combined with tacrolimus in the treatment of idiopathic membranous nephropathy. This study is designed well, and the results are interesting. After a minor revision, it can be accepted for publication. Comments: 1. Some minor language polishing should be corrected. 2. Tables should be edited. The “a” in the table 2 and table 3 should be noted and explained. 3. The limit of the study should be discussed.